Zenas Launches IgG4-RD Patient Education Platform

Zenas BioPharma's new platform offers resources and real-world stories for people living with the rare immune-related disease.

Updated on Nov. 17, 2026 in Diseases — General

Sunlit, empty community room with a single wooden chair beside a window overlooking a softly blurred tree-lined street.
Zenas BioPharma launched The Distance Between, a free educational platform for people living with IgG4-related disease and their physicians. AI Illustration. Upload story photo >

Zenas BioPharma launched The Distance Between, a community-focused educational platform for IgG4-related disease (IgG4-RD). The launch follows two online surveys the company commissioned in the United States in August 2026, covering 70 adults living with the disease and 61 physicians who manage it.

Why it matters

The surveys found that physicians and patients often discuss treatment goals and emotional well-being, but the two groups do not always report the same frequency of those conversations. The platform is intended to encourage those conversations between patients and their care teams for an estimated 25,000 people diagnosed with IgG4-RD in the United States.

The figures come from two company-commissioned online surveys with 70 adults living with IgG4-RD and 61 physicians who manage it, a sample too small to generalize to all patients. The source does not report a broader independent study, and the gap between physician and patient reports of treatment-goal discussions is not explained.

The players

Zenas BioPharma

A Nasdaq-listed (ZBIO) clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focused on developing treatments for immune-mediated diseases.

The details

The platform offers educational resources and real-world stories about IgG4-RD, a rare disease that can affect multiple organs. Zenas said the content was shaped by the survey findings and is meant to elevate lived experiences and support conversations between patients and care teams.

Timeline

  1. August 2026: Zenas commissioned the two online surveys in the United States.

  2. November 17, 2026: Zenas launched The Distance Between platform and released the survey findings.

Disease Awareness

Patient-facing education for rare diseases like IgG4-RD has grown as the 25,000 estimated US diagnoses leave many patients with limited reference material. The Distance Between is Zenas's contribution to that effort, built from its own survey data rather than an independent registry.

Patients and caregivers who want educational material on IgG4-RD can use The Distance Between platform to learn about the condition and prepare for conversations with their care teams. The platform's resources are aimed at helping people living with the disease understand their situation.

The takeaway

Patients with IgG4-RD may benefit from raising treatment goals and emotional health with their doctors, since the survey suggests those conversations do not always happen as often as physicians report. Asking about both at each visit can help close that gap.

Further reading

Explore more on Diseases — General for broader context on rare conditions like IgG4-RD.

More information

Visit the The Distance Between IgG4-RD educational platform to access the resources and real-world stories.

Source note: This article includes information reported by The Manila times.